Alistair Ellmer

Research Director Hanson Wade Intelligence

Seminars

Monday 3rd November 2025
ADC Toxicity: Exploring In Vivo Strategies & Clinical Topo1 Outcomes
11:30 am
  • Understanding state-of-play in NHP studies and implications for ADCs in the clinic
  • Investigating top-line Topo1 asset toxicity data and considering impact on the ADC space
  • Reviewing FIH trial adverse event data to help visualize the Topo1 toxicity landscape
Alistair Ellmer- 16th World ADC San Diego